The recall from the U.S. of tainted blood pressure medicines reached new heights as India’s Torrent Pharmaceuticals recalled 104 lots of losartan.

What does it take to run one of pharma’s biggest whales? As J&J CEO Alex Gorsky told Fortune, six years in the U.S. Army made all the difference.

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Biosims haven't worked, experts say. Instead, it's time to for an independent body to set fair biologic prices after the drugs lose exclusivity.

Roche’s Tecentriq scored some big wins lately, including a pair of first-in-class approvals. But in other cancers, it's decided to pull the plug.

Traditional generics bigwigs Teva, Mylan, Sandoz, Amneal and Endo have lost out to a group of six competitors in terms of U.S. weekly prescriptions.

Despite FDA warnings that patients who stopped treatment of Amgen's Prolia had a high risk of fractures, a consumer watchdog is calling for more.

Pharma’s reputation is holding steady with patient groups with an annual study finding 41% giving pharma good marks, similar to 43% the year before.